Adjuvant Cemiplimab for Cutaneous Squamous-Cell Carcinoma: Making the Case

In a phase 3, placebo-controlled trial involving patients with high-risk cSCC, cemiplimab yielded longer disease-free survival.

Cutaneous squamous-cell carcinoma (cSCC) is a localized disease that can be cured surgically in most patients; however, about 5% develop nodal or distant metastases in association with more-aggressive disease. Now, Rischin and colleagues present data from C-POST, the first randomized trial of adjuvant immunotherapy with cemiplimab (which targets programmed death 1 [PD-1]) in patients with resected high-risk cSCC.

A total of 415 participants were assigned to receive either cemiplimab or placebo for up to 48 weeks with a median follow-up of 24 months. Patients were generally well matched for high-risk characteristics between groups. Regarding the primary endpoint of disease-free survival (DFS), the hazard ratio for recurrence or death was 0.32…

Reviewing Author

Margaret Callahan, MD, PhD

Disclosures

Consultant/Advisory BoardBristol Myers Squibb, Immunocore, AstraZeneca/MedImmune

EquityMerus

Grant/Research SupportNIH, V Foundation

Margaret Callahan, MD, PhD

Disclosures

Consultant/Advisory BoardBristol Myers Squibb, Immunocore, AstraZeneca/MedImmune

EquityMerus

Grant/Research SupportNIH, V Foundation

Adjuvant Cemiplimab for Cutaneous Squamous-Cell Carcinoma: Making the Case

Topics

Reviewing Author